Medical Journals

Characterization of Functional Oligosaccharide Mimics of the Shigella Flexneri Serotype 2a O-antigen: Implications for the Development of a Chemically Defined Glycoconjugate Vaccine.

Authors:
  • Phalipon Armelle
  • Costachel Corina
  • Grandjean Cyrille
  • Thuizat Audrey
  • Guerreiro Catherine
  • Tanguy Myriam
  • Nato Farida
  • Vulliez-Le Normand Brigitte
  • Bélot Frédéric
  • Wright Karen
  • Marcel-Peyre Véronique
  • Sansonetti Philippe J
  • Mulard Laurence A

From: Unité de Pathogénie Microbienne Moléculaire, Institut National de la Santé et de la Recherche Médicale Unité 389. phalipon@pasteur.fr

Journal of immunology (Baltimore, Md. : 1950)

  • Publish Date: Feb 2006
  • ISSN: 0022-1767
  • Volume: 176
  • Issue: 3
  • Pages: 1686-94
  • Medium: Print
  • Language: English
  • Citation (JAMA): Phalipon Armelle, Costachel Corina, Grandjean Cyrille, et al. Characterization of Functional Oligosaccharide Mimics of the Shigella Flexneri Serotype 2a O-antigen: Implications for the Development of a Chemically Defined Glycoconjugate Vaccine.. J. Immunol. Feb 2006;176:1686-94

Abstract

Protection against reinfection with noncapsulated Gram-negative bacteria, such as Shigella, an enteroinvasive bacterium responsible for bacillary dysentery, is mainly achieved by Abs specific for the O-Ag, the polysaccharide part of the LPS, the major bacterial surface Ag. The use of chemically defined glycoconjugates encompassing oligosaccharides mimicking the protective determinants carried by the O-Ag, thus expected to induce an efficient anti-LPS Ab response, has been considered an alternative to detoxified LPS-protein conjugate vaccines. The aim of this study was to identify such functional oligosaccharide mimics of the S. flexneri serotype 2a O-Ag. Using protective murine mAbs specific for S. flexneri serotype 2a and synthetic oligosaccharides designed to analyze the contribution of each sugar residue of the branched pentasaccharide repeating unit of the O-Ag, we demonstrated that the O-Ag exhibited an immunodominant serotype-specific determinant. We also showed that elongating the oligosaccharide sequence improved Ab recognition. From these antigenicity data, selected synthetic oligosaccharides were assessed for their potential to mimic the O-Ag by analyzing their immunogenicity in mice when coupled to tetanus toxoid via single point attachment. Our results demonstrated that induction of an efficient serotype 2a-specific anti-O-Ag Ab response was dependent on the length of the oligosaccharide sequence. A pentadecasaccharide representing three biological repeating units was identified as a potential candidate for further development of a chemically defined glycoconjugate vaccine against S. flexneri 2a infection.

Mesh Headings (Keywords): Amino Acid Sequence, Animals, Carbohydrate Sequence, Drug Design, Dysentery, Bacillary, Glycoconjugates, Immunoglobulin G, Mice, Mice, Inbred BALB C, Molecular Mimicry, Molecular Sequence Data, O Antigens, Oligosaccharides, Serotyping, Shigella Vaccines, Shigella flexneri, Vaccines, Conjugate


Check for Full Text / PubMed Unique Identifier (PMID): 16424198


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.